AzTrials
AzTrials

COPDDiffLung3NCT06505902

Pulmonary Diffusing Capacity During Incremental Exercise in COPD

A study testing Exercise in people with COPD and Healthy, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: The combined measurement of pulmonary diffusing capacity for carbon monoxide (CO) and nitric oxide (NO) (DL,CO,NO) has recently been standardized and validated for clinical use. Read more about this study

Who is it for?
Ages 40 to 80 yearsHealthy volunteers can take part
Conditions the study is for
COPD, Healthy, Lung Diseases
What is being tested?
Exercise
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteDenmark
Study dates
15 Jul 2024to 1 Feb 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Men and women
  • 40-80 years
  • Mild to severe COPD (GOLD stage I to IIII)
  • Men and women
  • Age +/- 3 years of an included COPD patient

Who cannot join

  • Known ischaemic heart disease
  • Known heart failure
  • Cardiac arrythmias
  • Dementia or other severe neurological disease
  • Known vascular ischaemic disease
  • Symptoms of infection (bacterial/viral) within 2 weeks prior to the study
Show all 15Show fewer
  • Pregnancy
  • COPD
  • Known ischaemic heart disease
  • Known heart failure
  • Cardiac arrythmias
  • Dementia or other severe neurological disease
  • Known vascular ischaemic disease
  • Symptoms of infection (bacterial/viral) within 2 weeks prior to the study
  • Pregnancy

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Center for Aktiv Sundhed (CFAS), Rigshospitalet, Copenhagen, Denmark.

    Copenhagen, København Ø, 2100

Other trials in Denmark

About this study

Official title: Pulmonary Diffusing Capacity During Incremental Exercise in COPD: A Case-Control Study

Background:

The combined measurement of pulmonary diffusing capacity for carbon monoxide (CO) and nitric oxide (NO) (DL,CO,NO) has recently been standardized and validated for clinical use. It involves a noticeably short breath-hold time (≤5 seconds), making it feasible to perform on patients with chronic obstructive pulmonary disease (COPD). These patients have lower diffusing capacity and are unable to increase it during exercise, which is thought to be caused by changes in pulmonary perfusion potentially leading to exertional dyspnea. The aim of the present study is to examine whether pulmonary diffusing capacity for incremental exercise differs between patients with COPD and matched healthy controls.

Read more

Methods:

Inclusion of 12 individuals with mild-to-severe COPD and 12 healthy age- and sex-matched controls.

Design: Case-control study

Intervention: DL,CO,NO and arterial blood gases will be measured during exercise at a bicycle ergometer at 0, 20, 40, 60 and 80% of the individual's maximal workload.

Sample size: To detect a 15 mmol min-1 kPa-1 difference in DL,NO between groups at 60% of maximal workload, with a power of 90% and a significance level of 0.05, at least 12 subjects are required in each group. To account for potential dropouts, power will be permitted to decrease to 80%, corresponding to a total of 10 subjects in each group.

Statistical design: Linear mixed effect model and pairwise testing of estimated marginal means.

Perspective: This study will add to the understanding exertional dyspnoea in patients with COPD.

Read the detailed description

Introduction and background A pattern that applies to the majority of the more than 250 million people who suffer from chronic obstructive pulmonary disease (COPD) worldwide, is a downward spiral of exertional dyspnoea to poor quality of life, invalidity, and early death. A critical mechanism of exertional dyspnoea in these patients is thought to be reduced alveolar-capillary reserve, that is, a reduced ability to recruit and distend the pulmonary capillary bed to increase diffusing capacity upon an increase in cardiac output, which may be assessed by measuring the dual test pulmonary diffusing capacity (DL,CO,NO) during exercise. This technique permits up to 12 repeated manoeuvres within a session without affecting measurements, and it is thus ideal for assessing acute changes in pulmonary diffusing capacity and its components during various physiological manoeuvres. With this technique, the investigators have recently documented that alveolar-capillary recruitment, assessed by the change in the pulmonary diffusing capacity for nitric oxide (DL,NO) at a fixed workload of 60% of maximum, is blunted in COPD, seemingly in a severity-dependent fashion (unpublished observations). However, it is unknown whether this is already evident at low workloads, and/or whether it persists at near-maximal workloads, and it remains to be established to which extent this has an impact on pulmonary gas exchange, conventionally measured by the alveolar-arterial oxygen difference.

Aim The overall aim is to determine whether and how alveolar-capillary recruitment during incremental exercise differs between patients with mild-to-moderate COPD and healthy individuals.

Study design and recruitment 12 patients with mild-to-moderate COPD and 12 healthy age- and sex-matched controls will be included in the study, where DL,CO,NO will be measured at rest and during incremental workloads. Visit 0 consist of medical health interview and brief examination including blood pressure, heart rate and ECG measurement to investigate inclusion and exclusion criteria. Baseline measurements (Visit 1) will be performed to assess fitness and cardiopulmonary health status for the included patients and participants. The baseline measurements include cardiopulmonary exercise testing, lung function testing (dynamic spirometry, whole-body plethysmography and 10-second single-breath diffusing capacity for carbon monoxide), and an assessment of body composition. On Visit 2, which is at least two days later, an arterial catheter is inserted, after which DL,CO,NO and arterial blood gases are measured at rest, and at 20, 40, 60, and 80% of maximal workload on a bicycle ergometer, as determined during the cardiopulmonary exercise text on Visit 1.

Sample size Based on unpublished data in which a difference in DL,NO (mmol min-1 kPa-1) between COPD and control at 60% of maximal workload during cycling exercise, the power calculation was based on a two-sided independent samples t-test, with a power of 90% and a significance level (alpha) of 0.05. To detect a 15 mmol min-1 kPa-1 difference in DL,NO between groups at 60% of maximal workload, with a power of 90% and a significance level of 0.05, at least 12 subjects are required in each group. To account for potential dropouts, power will be permitted to decrease to 80%, corresponding to a total of 10 subjects in each group.

Statistical procedure The investigators will perform a linear mixed effect model with group and time as factors with participant as random effect accounting for repeated measures. The investigators will then perform pairwise testing of estimated marginal means from our mixed effect model to test for between group differences and within group differences. The investigators will perform Holm correction due to multiple testing.

General information This study is novel as it investigates pulmonary capillary recruitment in COPD, which is thought to be an important mechanism of exertional dyspnoea, which have primarily only been discussed in theoretical terms in previous studies. This study will be conducted in accordance with the regional ethical committee and the Declaration of Helsinki. Informed consent will be obtained from all study participants before enrolment and baseline testing.

Significance, novelty and expected impact The physiological assessments that are evaluated in the present study have the potential to be used provide information on the cause of dyspnoea in the individual COPD patient. This is relevant for the understanding of basic respiratory physiology and for designing future studies with interventions that aim to affect pulmonary capillary recruitment in COPD.

Being tested
Exercise
Medical subject headings
Pulmonary Disease, Chronic Obstructive, Lung Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ExerciseOther

    Exercise by bicycle and performing diffusing capacity measurements at the same time with arterial blood gasses.

Study groups in NCT06505902
Study groupRoleWhat they receive
COPD-patientsExperimentalCOPD-patients during diffusing capacity measurement during incremental exercise
Receives: Other: Exercise
Matched healthy volunteersExperimentalHealthy matched controls during diffusing capacity measurement during incremental exercise
Receives: Other: Exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary outcome

    Between-group difference in the change in DL,NO from rest to exercise as a function of workload

    Measured: Measured at day 2

Secondary outcomes (22)
  1. Key secondary outcome

    Between-group difference in the change of the alveolar-arterial oxygen difference from rest to exercise as a function of workload

    Measured: Measured at day 2

  2. Other secondary outcome

    Between-group difference in the change in DL,NO from rest to exercise as a function of VO2

    Measured: Measured at day 2

  3. Other secondary outcome

    Between-group difference in the change of the alveolar-arterial oxygen difference from rest to exercise as a function of VO2

    Measured: Measured at day 2

  4. Other secondary outcome

    Between-group difference in the change in cardiac output from rest to exercise as a function of workload

    Measured: Measured at day 2

  5. Other secondary outcome

    Between-group difference in the change in stroke volume from rest to exercise as a function of workload

    Measured: Measured at day 2

  6. Other secondary outcome

    Between-group difference in the change in heart rate from rest to exercise as a function of workload

    Measured: Measured at day 2

  7. Other secondary outcome

    Between-group difference in the change in mean arterial blood pressure from rest to exercise as a function of workload

    Measured: Measured at day 2

  8. Other secondary outcome

    Between-group difference in the change in cardiac output from rest to exercise as a function of VO2

    Measured: Measured at day 2

  9. Other secondary outcome

    Between-group difference in the change in stroke volume from rest to exercise as a function of VO2

    Measured: Measured at day 2

  10. Other secondary outcome

    Between-group difference in the change in heart rate from rest to exercise as a function of VO2

    Measured: Measured at day 2

  11. Other secondary outcome

    Between-group difference in the change in mean arterial blood pressure from rest to exercise as a function of VO2

    Measured: Measured at day 2

  12. Other secondary outcome

    Between-group difference in the change in PaO2 from rest to exercise as a function of workload and VO2

    Measured: Measured at day 2

  13. Other secondary outcome

    Between-group difference in the change in SaO2 from rest to exercise as a function of workload and VO2

    Measured: Measured at day 2

  14. Other secondary outcome

    Between-group difference in the change in PaCO2 from rest to exercise as a function of workload and VO2

    Measured: Measured at day 2

  15. Other secondary outcome

    Between-group difference in the change in pH from rest to exercise as a function of workload and VO2

    Measured: Measured at day 2

  16. Other secondary outcome

    Between-group difference in the change in base excess from rest to exercise as a function of workload and VO2

    Measured: Measured at day 2

  17. Other secondary outcome

    Between-group difference in the change in lactate from rest to exercise as a function of workload and VO2

    Measured: Measured at day 2

  18. Other secondary outcome

    Between-group difference in the change in respiratory rate from rest to exercise as a function of workload and VO2

    Measured: Measured at day 2

  19. Other secondary outcome

    Between-group difference in the change in DL,CO,5s from rest to exercise as a function of workload and VO2

    Measured: Measured at day 2

  20. Other secondary outcome

    Between-group difference in the change in DM from rest to exercise as a function of workload and VO2

    Measured: Measured at day 2

  21. Other secondary outcome

    Between-group difference in the change in VC from rest to exercise as a function of workload and VO2

    Measured: Measured at day 2

  22. Other secondary outcome

    Between-group difference in the change in VA from rest to exercise as a function of workload and VO2

    Measured: Measured at day 2

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jul 2024
  2. Study start15 Jul 2024
  3. Primary completion1 Feb 2025
  4. Study completion1 Feb 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
Matched case-control study
Masking
None (open label)
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06505902
Sponsor's protocol ID
H-24025935
Acronym
DiffLung3
Status last verified
Apr 2025
First submitted
8 Jul 2024
Last updated
24 Apr 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Exercise in people with COPD and Healthy, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary outcome (time frame: Measured at day 2). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
DiffLung3 Clinical Trial NCT06505902 | AzTrials